IMJUDO tremelimumab 25 mg/ 1.25 mL concentrated injection vial

Land: Australië

Taal: Engels

Bron: Department of Health (Therapeutic Goods Administration)

Werkstoffen:

tremelimumab, Quantity: 25 mg

Beschikbaar vanaf:

AstraZeneca Pty Ltd

farmaceutische vorm:

Injection, concentrated

Samenstelling:

Excipient Ingredients: disodium edetate; histidine hydrochloride monohydrate; polysorbate 80; trehalose dihydrate; water for injections; histidine

Toedieningsweg:

Intravenous Infusion

Eenheden in pakket:

1 vial

Prescription-type:

(S4) Prescription Only Medicine

therapeutische indicaties:

Hepatocellular Carcinoma (HCC),IMJUDO in combination with durvalumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior treatment with a PD-1/PD-L1 inhibitor.

Product samenvatting:

Visual Identification: Clear to slightly opalescent, colourless to slightly yellow solution, free from or practically free from visible particles.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 48 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Autorisatie-status:

Registered

Autorisatie datum:

2023-06-23